Lilrb1: A novel diagnostic b-cell marker to distinguish neoplastic b lymphoblasts from hematogones

Silvia Saumell Tutusaus, Elaina Pirruccello, Franklin Fuda, Hywyn Churchill, Dong Chen, Cheng Cheng Zhang, Weina Chen

Research output: Contribution to journalArticlepeer-review


Objectives: New B-cell markers are needed for monitoring B lymphoblastic leukemia (B-ALL) in the era of immunotherapies directed against CD19 and CD22. The expression of leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) on hematogones in bone marrow (BM) and neoplastic B lymphoblasts has not yet been systematically investigated. Methods: We assessed LILRB1 expression pattern on B cells in 19 control BMs and 22 B-ALL cases by flow cytometry. Results: In all cases, mature B cells and hematogones exhibited a consistent pattern of LILRB1 expression with variable intensity over different stages of maturation, including a characteristic V-shaped pattern on hematogones. While neoplastic B lymphoblasts in all cases expressed LILRB1, the pattern of expression was distinctly abnormal relative to hematogones (loss of the dynamic pattern in all cases and abnormal expression levels in 83% of cases). Conclusions: LILRB1 is a novel diagnostic B-cell marker to aid in distinguishing neoplastic B lymphoblasts from hematogones.

Original languageEnglish (US)
Pages (from-to)941-949
Number of pages9
JournalAmerican journal of clinical pathology
Issue number6
StatePublished - Dec 1 2021


  • Anti-CD22
  • B-lymphoblastic leukemia
  • Flow cytometry
  • LILRB1
  • Minimal residual disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Lilrb1: A novel diagnostic b-cell marker to distinguish neoplastic b lymphoblasts from hematogones'. Together they form a unique fingerprint.

Cite this